Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
JR-032
print preview
bookmark
share with colleague
General Information
Company
JCR Pharmaceuticals Co. Ltd.
Description
Recombinant iduronate-2-sulfatase rDNA origin manafactured using serum-free culture technology
Molecular Target
Mechanism of Action
Enzyme replacement therapy
Latest Stage of Development
Preclinical
Indication
Mucopolysaccharidosis
Partner
GlaxoSmithKline plc
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy